Clinical Trial Update: Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation [Phase 2]

View source ↗

Summary

A completed Phase 2 trial evaluating beta-hydroxy-beta-methylbutyrate (HMB) to counteract muscle loss in men with prostate cancer receiving androgen ablation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• beta-hydroxy-beta-methylbutyrate (beta-hydroxy-beta-methylbutyrate)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-09-22